VOLITIONRX LIMITED VolitionRx Limited appointed Dr. Andrew Retter as its Chief Medical Officer, effective April 1, 2024. Dr. Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs. Andrew is an Intensive Care Consultant at Guy's and St.
Thomas' NHS Foundation Trust in London, where he has worked as a Consultant since 2014 and leads Clinical Governance in Critical Care. He specializes in the management of severe respiratory failure, ECMO and thrombosis. Dr. Retter is the only Consultant in the UK to hold dual entry on the specialist register in Intensive Care and Haematology, and provides national guidance on the management of complex haematology patients in critical care.
Dr. Retter has worked with Volition in an advisory capacity since January 2022, to help guide the product development and clinical utility of Nu.Q NETs ? a CE-marked routine blood test to detect diseases associated with NETosis, such as sepsis.
